Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for cancer prevention in Lynch syndrome (CaPP3)
NCT02497820Phase 3Not yet recruiting
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Sep 2016
- Primary completion
- Sep 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aspirin in Lynch syndrome (LS), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Cumulative Lynch syndrome cancer incidence at 5 years. Planned start Sep 2016; status: not yet recruiting.
02
Drugs
aspirin
03
Conditions
Lynch syndrome (LS)
Beyond the preview
Go deeper on NCT02497820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497820.